{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65736d39d32e730012c98919/6a105bfc80978431daf3c12d?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"AI Scientists, Stock Tumble, Patent Lawsuit, and New Partnerships","description":"<p>Agentic AI is growing in its applications. Google DeepMind and Edison are leveraging the growing capabilities by developing AI Scientists. These platforms are poised to streamline the scientific process, aiding human scientists with a variety of tasks. Meanwhile, despite positive data in its Phase III DMD therapy trial, Regenxbio’s stock fell for a variety of reasons. 10X Genomics and Harvard University are suing Element Biosciences over patents for a multiomics platform. Finally, Bristol Meyers Squibb is partnering with Hengrui Pharma to develop 13 early-stage programs with the potential to grow their investment to a predicted $15 billion in sales.</p><p><br></p><p>&nbsp;</p><p>Join <em>GEN</em> editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.&nbsp;</p><p>&nbsp;</p><p>Listed below are links to the <em>GEN</em> stories referenced in this episode of <em>Touching Base</em>:&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/artificial-intelligence/google-deepmind-and-edison-are-building-the-ai-scientist/\" rel=\"noopener noreferrer\" target=\"_blank\">Google DeepMind and Edison Are Building the AI Scientist </a></p><p>By Fay Lin, PhD, <em>GEN Edge</em>, May 19, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/translational-medicine/stockwatch-regenxbio-tumbles-despite-positive-pivotal-data-for-dmd-gene-therapy-candidate/\" rel=\"noopener noreferrer\" target=\"_blank\">StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate</a></p><p>By Alex Philippidis, <em>GEN Edge</em>, May 17, 2026</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/omics/10x-genomics-harvard-target-elements-multiomics-platform-in-patent-lawsuit/\" rel=\"noopener noreferrer\" target=\"_blank\">10x Genomics, Harvard Target Element’s Multiomics Platform in Patent Lawsuit </a></p><p>By Alex Philippidis, <em>GEN Edge</em>, May 12, 2026</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/drug-discovery/bms-hengrui-pharma-partner-on-13-programs-in-up-to-15-2b-collaboration/\" rel=\"noopener noreferrer\" target=\"_blank\">BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration </a></p><p>By Alex Philippidis, <em>GEN Edge</em>, May 13, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/category/multimedia/podcasts/touching-base/\" rel=\"noopener noreferrer\" target=\"_blank\">Touching Base Podcast</a>&nbsp;</p><p>Hosted by Corinna Singleman, PhD&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.insideprecisionmedicine.com/category/multimedia/podcasts/\" rel=\"noopener noreferrer\" target=\"_blank\">Behind the Breakthroughs</a>&nbsp;</p><p>Hosted by Jonathan D. Grinstein, PhD&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.insideprecisionmedicine.com/multimedia/virtual-event/the-state-of-precision-medicine-2/\" rel=\"noopener noreferrer\" target=\"_blank\">The State of Precision Medicine Summit</a></p><p>Join us June 3, 2026</p>","author_name":"Genetic Engineering & Biotechnology News (GEN)"}